Compare Crispr Therapeutics AG (CRSP) vs EOG Resources Inc (EOG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crispr Therapeutics AG vs EOG Resources Inc — how do they compare? Crispr Therapeutics AG trades at $51.39 (market cap $4.97B), while EOG Resources Inc trades at $137.54 (market cap $73.51B). The key difference: EOG Resources Inc is far larger — about 14.8× Crispr Therapeutics AG's market cap, and EOG Resources Inc pays a 2.96% dividend while Crispr Therapeutics AG pays none. Which is the better fit depends on your goals.
| CRSP | EOG | |
|---|---|---|
Market Cap | $4.97B | $73.51B |
Sector | Health | Energy |
52-Week High | $76.78 | $149.89 |
52-Week Low | $44.34 | $101.78 |
Enterprise Value | $3.32B | $77.97B |
Dividend Yield | — | 2.96% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRSP trades at $50.63, down 5.1% over 24 hours, amid a bearish technical signal. The company shows deep losses with a net income margin of -56,853.4% in 2025 and negative cash flow from operations. However, analyst consensus remains optimistic with a $74.50 price target, and recent news highlights FDA approval for Casgevy, expanding its gene therapy market.
The outlook hinges on commercial execution of Casgevy and pipeline progress, offering high growth potential in gene editing. Key risks include sustained cash burn, competitive pressures, and regulatory hurdles. Despite current financial challenges, strong analyst buy ratings suggest confidence in long-term value.
EOG Resources trades at $139.61, up 4.11% with a bullish technical outlook. The stock shows strong profitability with a net margin of 23.39% and ROE of 18.19%, supported by consistent earnings beats. Valuation ratios like P/E of 13.73 and EV/EBITDA of 6.6 appear attractive relative to historical levels. Recent news highlights operational excellence and dividend stability, with Q2 2026 earnings anticipated on August 5, 2026.
The outlook remains positive with a consensus price target of $156.40, implying 12% upside. Risks include oil price volatility and elevated capital expenditures, but EOG's low-cost production and solid balance sheet provide resilience. Analyst sentiment is strongly bullish with no sell ratings, reinforcing the investment case for growth and income.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →About EOG Resources Inc
EOG Resources is an oil and gas producer with acreage in several U.S. shale plays, including the Permian Basin, the Eagle Ford, and the Bakken. At the end of 2021, it reported net proved reserves of 3.7 billion barrels of oil equivalent. Net production averaged 829 thousand barrels of oil equivalent per day in 2021 at a ratio of 72% oil and natural gas liquids and 28% natural gas.
Read more on EOG →
